SCHEMBL1310490

SCHEMBL1310490

Fc1cc(-c2nc(N3CCOCC3)c3oc4ccccc4c3n2)c2cn[nH]c2c1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.53
MAPK1 P28482 2/20 0.53
PIK3CA P42336 15/20 0.47
PIK3CD O00329 4/20 0.47
PIK3CG P48736 4/20 0.47
TSHR P16473 2/20 0.46
PIK3CB P42338 5/20 0.45
KDM4E B2RXH2 2/20 0.45
MAPT P10636 1/20 0.45
HSD17B10 Q99714 1/20 0.45
HRH4 Q9H3N8 1/20 0.45
MTOR P42345 1/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16378554 0.89 LMNA (0.50) LMNAMAPK1PIK3CAPIK3CDPIK3CG
SCHEMBL1310092 0.89 LMNA (0.50) LMNAMAPK1PIK3CAPIK3CDPIK3CG
SCHEMBL1309544 0.87 PIK3CA (0.61) LMNAMAPK1PIK3CAPIK3CDPIK3CG
SCHEMBL1310153 0.86 PIK3CD (0.57) LMNAMAPK1PIK3CAPIK3CDPIK3CG
SCHEMBL1311222 0.80 PIK3CA (0.60) LMNAMAPK1PIK3CAPIK3CDPIK3CG
SCHEMBL1310077 0.80 LMNA (0.55) LMNAMAPK1PIK3CAPIK3CDPIK3CG
SCHEMBL1310791 0.79 PIK3CA (0.51) PIK3CAPIK3CDPIK3CGPIK3CBMTOR
SCHEMBL1310876 0.78 PIK3CA (0.53) PIK3CAPIK3CDPIK3CGPIK3CBMTOR
SCHEMBL1310913 0.76 PIK3CA (0.58) LMNAMAPK1PIK3CAPIK3CDPIK3CG
SCHEMBL1309730 0.75 LMNA (0.64) LMNAMAPK1PIK3CAPIK3CDPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921361-B2 Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes UNIVERSITY OF BASEL (CH) 2014-12-30 US disclosed
US-8921361-B2 Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes UNIVERSITY OF BASEL (CH) 2014-12-30 US disclosed
US-8921361-B2 Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes UNIVERSITY OF BASEL (CH) 2014-12-30 US disclosed
US-20110275762-A1 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2011-11-10 US disclosed
US-20110275762-A1 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2011-11-10 US disclosed
US-20110275762-A1 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2011-11-10 US disclosed
WO-2010052569-A2 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275762-A1 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES MTOR, PIK3CA, PIK3CD LMNA 2709/4885MAPK1 216/4885PIK3CA 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.